查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972732

鎦-177市場：按產品類型、生產技術、應用、最終用戶和分銷管道分類的全球預測 - 2026年至2032年

Lutetium-177 Market by Product Type, Production Technology, Application, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鎦-177 市場價值將達到 10.5 億美元，到 2026 年將成長到 12.3 億美元，到 2032 年將達到 31.3 億美元，年複合成長率為 16.76%。

主要市場統計數據
基準年 2025 10.5億美元
預計年份：2026年 12.3億美元
預測年份 2032 31.3億美元
複合年成長率 (%) 16.76%

鎦-177 全面概述：科學基礎、臨床前景、生產流程、法規環境及相關人員影響

鎦-177已成為精準腫瘤學和核子醫學交叉領域的關鍵放射性核素，推動了靶向分子配體與BETA射線同位素有效載荷相結合的新治療方法趨勢。過去十年，臨床開發逐步證實了靶向放射性核素療法的治療潛力，吸引了臨床醫生、放射性藥物專家和戰略相關人員的廣泛關注，他們都在尋求能夠兼顧疾病控制和可控毒性的治療方法。在生產和營運方面，鎦-177帶來了獨特的複雜性，涉及同位素採購、放射性標記流程、低溫運輸物流以及跨司法管轄區的監管合規性。

一場變革性的轉變正在重塑鎦-177 的發展，涵蓋科學創新、供應鏈現代化、監管演變和臨床部署趨勢。

鎦-177領域正經歷著一場變革性的轉型，其驅動力來自科學技術創新、不斷變化的監管環境以及自動化和供應鏈管理的進步。在科學方面，標靶配體和連接子化學的改進提高了腫瘤選擇性和藥物動力學特性，使更多類型的標靶得以研究。同時，更先進的劑量測定工具和影像生物標記的出現，使臨床醫生能夠最佳化患者選擇、制定個人化治療方案、改善風險獲益分析，並支持更廣泛的臨床應用。

評估美國關稅於 2025 年生效對鎦-177 進口、供應韌性、成本結構和戰略應對措施的累積影響。

美國2025年實施的關稅政策正促使處理鎦-177的營業單位重新評估其籌資策略、供應商關係和製造地。關稅的實施將透過關鍵生產過程的本地化和物流重組，為緩解不斷成長的成本壓力創造結構性獎勵。實際上，這正促使各企業加快對國內放射性藥物生產能力​​的投資，尋求與合約研發生產機構（CDMO）的區域合作，並探索分散同位素和前體來源（跨越多個供應商和司法管轄區）的對沖策略。

針對鎦-177的商業化，將進行基於細分市場的分析，重點關注每種產品的形式、給藥途徑、目標疾病類別、自動化技術以及最終用戶特徵。

精準的細分觀點揭示了商業性和臨床機會與實際營運的交匯點，而理解這些細分領域對於制定有針對性的策略至關重要。產品類型（試劑盒和即用型製劑）的差異，為終端使用者帶來了截然不同的工作流程。試劑盒強調現場放射性標記技術和靈活的給藥方案，而即用型製劑則優先考慮便利性和簡化的現場操作。給藥途徑仍是臨床上的關鍵因素；腫瘤內給藥可實現局部高劑量給藥，而靜脈注射支持全身性標靶治療策略。每種給藥途徑對製劑、無菌性和臨床監測都有其獨特的要求。

鎦-177區域策略展望引言：重點在於需求因素、基礎設施差異、監管狀況與區域合作機會

區域趨勢顯著影響相關人員進行臨床部署、製造地和建立夥伴關係的方式，因此，基於地理因素的策略至關重要。在美洲，對專業癌症治療中心和集中式放射性藥物網路的投資，已構建起一個成熟的臨床生態系統，為開展高級臨床試驗活動提供了支持，並為商業化鋪平了道路。在該地區，結合臨床支援和物流可靠性的綜合解決方案往往更受歡迎，相關人員應優先考慮合作，以確保可預測的供應和流程培訓，同時滿足臨床需求。

在鎦-177價值鏈中營運的主要企業的競爭與合作概況（重點關注能力、夥伴關係關係、製造地和智慧財產權策略）

主要企業和機構正透過在放射化學、臨床開發、生產規模和策略夥伴關係等方面的差異化能力，塑造競爭格​​局。在整個價值鏈中，一些機構專注於提供整合解決方案，將同位素生產與端到端的放射性標記服務和臨床支援相結合，從而更嚴格地控制品質參數並確保供應的連續性。另一些機構則專注於提供模組化服務，例如客製化標記服務、集中式氯化鎦-177供應或預標記治療組件，使臨床團隊和中小企業能夠在無需大量資本投入的情況下獲得高品質產品。

為行業領導者提供切實可行的建議，以透過最佳化供應、臨床合作、監管策略和商業性準備來加速鎦-177 的應用。

業界領導企業可透過推動一系列切實可行的合作舉措，協調科學、監管和商業性需求，從而加速鎦-177療法的部署。首先，需要投資建構具有韌性的供應鏈結構，將本地放射性藥物生產能力​​與策略性第三方夥伴關係關係結合，以減輕貿易政策變化和物流限制對營運的影響。其次，應優先推動自動化和標準化合成通訊協定，以減少放射性標記結果的差異，提高處理能力，並促進各生產設施符合法規要求。

透明的調查方法，解釋了用於得出見解的主要和次要來源、檢驗程序、細分邏輯和分析框架。

本分析的研究途徑結合了對同儕審查文獻、監管指導文件、放射性藥物生產技術標準的系統性回顧，以及對臨床、生產和分銷領域專家的定性訪談。對放射化學家、參與靶向放射性核素檢測的臨床研究人員、放射性藥物部門負責人和供應鏈經理的訪談，旨在了解實際運作中的限制因素和新興的最佳實踐。二級資訊來源則提供了與鎦-177應用相關的配體開發、劑量測定調查方法和穩定性概況等技術背景資訊，從而補充了這些發現。

一份策略概要，概述了鎦-177對相關人員的影響、當前挑戰、新機會和短期行動重點。

總之，鎦-177正處於一個策略轉折點，科學成熟、營運創新和不斷變化的政策環境在此交匯，為相關人員帶來機會和挑戰。從臨床實驗性化合物到臨床規模治療計畫的轉變，需要對可重複的生產、供應鏈的穩定性以及全面的臨床證據的建立進行協調一致的投資。諸如監管差異、低溫運輸物流以及對訓練有素的放射化學工程師的需求等持續存在的挑戰，必須透過將商業性獎勵與臨床能力建設相結合的合作模式來解決。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：鎦-177市場：依產品類型分類

  • 載體添加的鎦-177
  • 不含載體的鎦-177

第9章鎦-177市場及其製造技術

  • 利用迴旋加速器法進行生產
  • 基於核子反應爐的生產

第10章：鎦-177市場：依應用領域分類

  • 研究和臨床前階段
    • 體外研究
    • 體內動物模型
  • 治療藥物
    • 骨髓惡性腫瘤
    • 神經內分泌腫瘤（SSTRs）
    • 骨轉移的安寧療護
    • 前列腺癌（PSMA）

第11章：鎦-177市場：依最終用戶分類

  • 醫院
  • 門診部
  • 製藥和生物技術公司
  • 研究機構
  • 專科診所

第12章：鎦-177市場：依通路分類

  • 直接購買
  • 間接

第13章：鎦-177市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：鎦-177市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：鎦-177市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國鎦-177市場

第17章：中國的鎦-177市場

第18章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • China National Nuclear Corporation
  • Curium Pharma
  • Eckert & Ziegler Radiopharma GmbH
  • Framatome
  • Fusion Pharmaceuticals Inc. by AstraZeneca
  • IBA Radiopharma Solutions
  • Isotopia Molecular Imaging Ltd.
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • Nuclear Research and Consultancy Group
  • RadioMedix, Inc.
  • RayzeBio, Inc. by Bristol Myers Squibb
  • Revvity Inc.
  • SHINE Technologies, LLC
  • Telix Pharmaceuticals Limited
Product Code: MRR-9A6A6F2977DA

The Lutetium-177 Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.23 billion in 2026, with a CAGR of 16.76%, reaching USD 3.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.23 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 16.76%

Comprehensive introduction to Lutetium-177: scientific foundations, clinical promise, manufacturing pathways, regulatory context and stakeholder implications

Lutetium-177 has emerged as a pivotal radionuclide at the intersection of precision oncology and nuclear medicine, driving a new wave of therapeutic modalities that couple targeted molecular ligands with beta-emitting isotope payloads. Over the past decade, clinical developments have progressively validated the therapeutic potential of targeted radionuclide therapies, increasing interest among clinicians, radiopharmacists, and strategic stakeholders who seek treatments that offer both disease control and manageable toxicity profiles. From a manufacturing and operational standpoint, Lutetium-177 introduces distinct complexities related to isotope sourcing, radiolabeling workflows, cold-chain logistics, and regulatory compliance across jurisdictions.

This introduction frames Lutetium-177 not only as a scientific asset but also as a commercial and logistical challenge that requires multidisciplinary coordination. Stakeholders must integrate clinical evidence, radiochemistry expertise, and supply chain design to transition candidates from preclinical validation into routine therapeutic use. Consequently, organizations pursuing opportunities in this space should prioritize reproducible radiolabeling processes, robust quality assurance practices, and proactive regulatory engagement to minimize translational friction and accelerate clinical adoption.

Transformative shifts reshaping Lutetium-177 development encompassing scientific innovations, supply chain modernization, regulatory evolution and clinical adoption dynamics

The landscape for Lutetium-177 is undergoing transformative shifts driven by converging scientific innovations, evolving regulatory frameworks, and advances in automation and supply chain orchestration. On the scientific front, improvements in targeting ligands and linker chemistry are yielding enhanced tumor selectivity and pharmacokinetic profiles, which in turn are expanding the range of target classes under investigation. Parallel to these advances, the emergence of more sophisticated dosimetry tools and imaging biomarkers is enabling clinicians to refine patient selection and personalize therapeutic regimens, thereby improving risk-benefit considerations and supporting broader clinical uptake.

Operationally, the field is moving toward modular and automated production models that reduce variability in radiolabeling and enable scalable, reproducible manufacturing across centralized and decentralized facilities. Regulatory pathways are adapting to accommodate the unique attributes of radiopharmaceuticals, with agencies clarifying expectations for sterility, radiochemical purity, and stability. These changes collectively reduce translational friction and invite new entrants, but they also raise competitive intensity around service capabilities, supply security, and integrated clinical support. As a result, the next phase of growth will favor organizations that can combine scientific differentiation with end-to-end operational excellence.

Assessing the cumulative consequences of United States tariffs effective in 2025 on Lutetium-177 imports, supply resilience, cost structures and strategic responses

The introduction of United States tariffs in 2025 has prompted a re-evaluation of procurement strategies, supplier relationships, and manufacturing footprints for entities engaged with Lutetium-177. Tariff impositions create a structural incentive to localize critical production steps or to reconfigure logistics to mitigate incremental cost pressures. In practice, this leads organizations to accelerate investments in domestic radiopharmacy capacity, to pursue regional partnerships with contract development and manufacturing organizations, and to explore hedging strategies that diversify isotope and precursor sourcing across multiple suppliers and jurisdictions.

Beyond cost implications, tariffs influence the cadence of strategic decision-making. Providers with long-term supply agreements and vertically integrated operations have greater flexibility to absorb transitional disruption, while smaller research centers and early-stage developers may face near-term access constraints that require operational adaptations such as shared radiochemistry facilities or collaboration with centralized compounding entities. Over time, policy-driven shifts will also shape competitive dynamics by altering the relative attractiveness of manufacturing investments in different regions and by incentivizing cross-border partnerships that internalize tariff impacts. Consequently, organizations should model tariff scenarios as part of their supply chain risk assessments and prioritize contingency plans that preserve clinical continuity and trial integrity.

Segment-driven insights for Lutetium-177 commercialization spotlighting product formats, routes of administration, target classes, automation and end-user nuances across offerings

A nuanced segmentation perspective reveals where commercial and clinical opportunities intersect with operational realities, and understanding these segments is essential for targeted strategy. Product type distinctions between Kits and Ready To Use formats create fundamentally different workflows for end users: kits emphasize on-site radiolabeling expertise and flexible scheduling, whereas ready-to-use formats prioritize convenience and reduced on-site complexity. Route of administration remains an important clinical axis, with intratumoral delivery enabling localized high-dose applications and intravenous administration supporting systemic targeting strategies; each route carries distinct requirements for formulation, sterility, and clinical monitoring.

Formulation choices between freeze-dried and liquid presentations influence stability, cold-chain logistics, and time-to-use constraints, thereby shaping distribution models and facility requirements. The product classification into Carrier-Added and No-Carrier-Added Lutetium-177 further stratifies the value chain: carrier-added variants and no-carrier-added variants each span custom labeling services, Lu-177 chloride intermediates, and pre-labeled therapeutic products, and these permutations affect regulatory pathways, radiochemical purity profiles, and end-user preparation needs. Target classes under investigation range from fibroblast activation protein, GRPR, and integrins to prostate-specific membrane antigen and somatostatin receptors; within those classes, PSMA-targeting approaches split into antibody-based constructs and small-molecule inhibitors, while somatostatin receptor-directed therapies predominantly utilize peptide analogues with defined pharmacokinetic behaviors.

End-user segmentation encompasses academic and research institutes, contract development and manufacturing organizations and contract research organizations, hospitals and cancer centers, nuclear medicine and radiopharmacy setups, and pharmaceutical and biotechnology companies. Hospitals and cancer centers exhibit a split between community care settings and tertiary care centers, each with varying procedural volumes and infrastructure. Nuclear medicine and radiopharmacy operations differentiate between centralized facilities that support multiple hospitals and on-site facilities embedded within clinical centers. Pharmaceutical and biotechnology firms include both generics and suppliers as well as innovators focused on novel radioligands. Automation level is another critical lens: fully automated synthesis platforms deliver consistency and throughput, semi-automated workflows balance flexibility and control, and manual labeling persists in low-volume or highly customized environments. A supplementary end-user view distinguishes hospitals from specialty clinics based on procedural complexity and case mix. Distribution channels fall into direct purchase and indirect pathways, with indirect distribution further bifurcated into retailer and wholesaler networks that influence inventory strategy and availability. Finally, application segmentation separates research and preclinical activities-including both in vitro studies and in vivo animal models-from therapeutic use cases that encompass hematologic malignancies, neuroendocrine tumors tied to somatostatin receptors, palliative treatments for bone metastases, and prostate cancer therapies centered on PSMA targeting. Together, these segmentation layers provide a multidimensional map for aligning product development, manufacturing design, reimbursement strategies, and clinical engagement plans.

Region-specific strategic outlook for Lutetium-177 deployment highlighting demand drivers, infrastructure gaps, regulatory landscapes and collaboration opportunities by geography

Regional dynamics materially influence how stakeholders approach clinical deployment, manufacturing placement, and partnership formation, and a geographically informed strategy is therefore indispensable. In the Americas, investment in specialized oncology centers and centralized radiopharmacy networks has created a mature clinical ecosystem that supports advanced trial activity and offers clear pathways for commercial rollout. This region tends to favor integrated solutions that combine clinical support with logistical reliability, and stakeholders should prioritize collaborations that ensure predictable supply and procedural training to capture clinical demand.

In Europe, the Middle East and Africa, regulatory heterogeneity and uneven infrastructure create both challenges and openings. Several countries in this broader region have advanced nuclear medicine capacities, but others require investment in cold-chain and sterile manufacturing to realize full clinical potential. Strategic entrants can benefit from phased approaches that combine centralized manufacturing hubs with capacity-building initiatives at tertiary care centers. Meanwhile, policy engagement with regional authorities is essential to streamline approvals and reimbursement frameworks.

The Asia-Pacific region is marked by rapid clinical adoption in select markets, growing pharmaceutical and radiochemistry expertise, and a growing appetite for local manufacturing to reduce import dependency. In several markets, strong public-sector investment in cancer care and localized clinical research programs presents opportunities for partnership and technology transfer. However, supply chain complexity and regulatory variance require tailored approaches that balance local production with regional distribution agreements. Across all regions, stakeholders should adapt strategies to local clinical pathways, regulatory expectations, and logistical realities while seeking scalable models that can be replicated across neighboring markets.

Competitive and collaborative profiles of key companies active in Lutetium-177 value chain emphasizing capabilities, partnerships, manufacturing footprints and IP positioning

Key corporate and institutional players are shaping the competitive topology through differentiated capabilities in radiochemistry, clinical development, manufacturing scale, and strategic partnerships. Across the value chain, some organizations emphasize integrated solutions that combine isotope production with end-to-end radiolabeling services and clinical support, enabling tighter control over quality parameters and supply continuity. Others specialize in modular service offerings-such as custom labeling services, centralized Lu-177 chloride supply, or pre-labeled therapeutic components-that allow clinical groups and smaller firms to access high-quality inputs without large capital outlays.

Collaboration patterns reveal a pragmatic orientation: alliances between research institutions, contract manufacturers, and clinical centers are accelerating trial execution and broadening access to complex radiotherapeutics. Intellectual property positioning centers on ligand chemistries, linker technologies, and manufacturing processes that improve radiochemical yield and stability. Meanwhile, firms that invest in automation and validated synthesis platforms secure operational advantages through reproducibility and throughput. For prospective partners and investors, evaluating company capabilities requires attention to manufacturing footprints, regulatory track records, clinical pipeline depth, and a demonstrated ability to scale from early-phase studies to routine therapeutic use. In short, the most compelling players combine technical depth with operational reliability and clear pathways to clinical adoption.

Actionable recommendations for industry leaders to accelerate Lutetium-177 adoption through supply optimization, clinical partnerships, regulatory strategy and commercial readiness

Industry leaders can accelerate adoption of Lutetium-177 therapies by pursuing a set of pragmatic, coordinated actions that align scientific, regulatory, and commercial imperatives. First, invest in resilient supply chain architectures that combine localized radiopharmacy capacity with strategic third-party partnerships to mitigate the operational impact of trade policy changes and logistical constraints. Second, prioritize automation and standardized synthesis protocols to reduce variability in radiolabeling outcomes, increase throughput, and facilitate regulatory compliance across sites.

Third, deepen clinical partnerships through joint protocols that validate dosimetry, patient selection criteria, and outcome measures; these collaborations will shorten time to evidence required for broader clinical acceptance. Fourth, design product portfolios that address distinct end-user needs by offering both kits for flexible on-site preparation and ready-to-use formats for centers seeking minimal operational burden. Fifth, proactively engage with regulatory authorities to clarify expectations for radiochemical characterization and sterility testing, and to streamline pathways for both carrier-added and no-carrier-added product variants. Finally, complement clinical and manufacturing investments with commercial enablement-educational programs for prescribing clinicians, reimbursement strategy development, and targeted distribution models-to ensure that supply and clinical capability translate into patient access and sustained utilization.

Transparent research methodology describing primary and secondary sources, validation steps, segmentation logic and analytical frameworks used to derive insights

The research approach underpinning this analysis combined systematic review of peer-reviewed literature, regulatory guidance documents, technical standards for radiopharmaceutical production, and qualitative interviews with domain experts across clinical, manufacturing, and distribution functions. Primary interviews focused on radiochemistry specialists, clinical investigators involved in targeted radionuclide trials, heads of radiopharmacy operations, and supply chain managers to capture real-world operational constraints and emerging best practices. Secondary sources complemented these insights by providing technical context on ligand development, dosimetry methodologies, and stability profiles relevant to Lutetium-177 applications.

Analytical rigor was ensured through cross-validation of qualitative inputs with documented procedural standards and publicly available clinical trial protocols. Segmentation logic was explicitly defined to reflect product format, route of administration, formulation, tracer class, end-user type, automation level, distribution channel, and application scope, allowing for layered analysis that connects technical attributes to operational and commercial implications. Where uncertainty existed, sensitivity checks and scenario analyses were used to delineate plausible outcomes and to highlight levers that stakeholders can influence to reduce execution risk. This methodological blend provides a robust foundation for the strategic recommendations and regional insights presented.

Concluding strategic synthesis summarizing Lutetium-177 implications for stakeholders, persistent challenges, emergent opportunities and priorities for near-term action

In conclusion, Lutetium-177 stands at a strategic inflection point where scientific maturation, operational innovation, and changing policy conditions converge to create both opportunity and complexity for stakeholders. The transition from investigational compounds to clinically scaled therapeutic programs requires coordinated investment in reproducible manufacturing, supply resilience, and comprehensive clinical evidence generation. Persistent challenges-such as regulatory heterogeneity, cold-chain logistics, and the need for trained radiochemistry personnel-must be addressed through collaborative models that align commercial incentives with clinical capacity-building.

Yet the opportunities are substantial: targeted radionuclide therapies have demonstrated potential across multiple target classes and indications, and advances in automation, dosimetry, and ligand chemistry continue to expand clinical applicability. Strategic actors that integrate technical differentiation with robust operational strategies and proactive regulatory engagement will be best positioned to capture value. The path forward demands disciplined execution, targeted partnerships, and an unwavering focus on translating clinical promise into accessible, reliable therapeutic options for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lutetium-177 Market, by Product Type

  • 8.1. Carrier-Added Lutetium-177
  • 8.2. No-Carrier-Added Lutetium-177

9. Lutetium-177 Market, by Production Technology

  • 9.1. Cyclotron-Based Production
  • 9.2. Reactor-Based Production

10. Lutetium-177 Market, by Application

  • 10.1. Research & Preclinical
    • 10.1.1. In Vitro Studies
    • 10.1.2. In Vivo Animal Models
  • 10.2. Therapeutics
    • 10.2.1. Hematologic Malignancies
    • 10.2.2. Neuroendocrine Tumors (SSTR)
    • 10.2.3. Palliative Bone Metastases
    • 10.2.4. Prostate Cancer (PSMA)

11. Lutetium-177 Market, by End-User

  • 11.1. Hospitals
  • 11.2. Outpatient Centers
  • 11.3. Pharmaceutical and Biotechnology Companies
  • 11.4. Research Institutions
  • 11.5. Specialty Clinics

12. Lutetium-177 Market, by Distribution Channel

  • 12.1. Direct Purchase
  • 12.2. Indirect

13. Lutetium-177 Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Lutetium-177 Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Lutetium-177 Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Lutetium-177 Market

17. China Lutetium-177 Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals, Inc.
  • 18.6. Bayer AG
  • 18.7. BWX Technologies, Inc.
  • 18.8. Cardinal Health, Inc.
  • 18.9. China National Nuclear Corporation
  • 18.10. Curium Pharma
  • 18.11. Eckert & Ziegler Radiopharma GmbH
  • 18.12. Framatome
  • 18.13. Fusion Pharmaceuticals Inc. by AstraZeneca
  • 18.14. IBA Radiopharma Solutions
  • 18.15. Isotopia Molecular Imaging Ltd.
  • 18.16. ITM Isotope Technologies Munich SE
  • 18.17. Lantheus Holdings, Inc.
  • 18.18. NorthStar Medical Radioisotopes, LLC
  • 18.19. Novartis AG
  • 18.20. NTP Radioisotopes SOC Ltd.
  • 18.21. Nuclear Research and Consultancy Group
  • 18.22. RadioMedix, Inc.
  • 18.23. RayzeBio, Inc. by Bristol Myers Squibb
  • 18.24. Revvity Inc.
  • 18.25. SHINE Technologies, LLC
  • 18.26. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS LUTETIUM-177 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 169. G7 LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. NATO LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 177. NATO LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)